Time to rethink COVID vaccine updates for 2026

Health experts now face a key decision: should next year’s COVID vaccines focus on the newest virus strains? U. S. regulatory advisors meet Thursday to vote on whether to switch from the current LP. 8. 1 target to newer variants like XFG, which now dominates new infections. This isn’t just about science—it’s about keeping up with a moving target. The JN. 1 family of variants has kept evolving since 2023, creating a patchwork of subvariants across countries. While some authorities prefer targeting a single dominant strain, others argue this misses the bigger picture of how fast viruses change.Vaccine makers have already said they can adapt, but getting the updated doses ready won’t be instant. The three main shots in the U. S. —from Moderna, Pfizer, and Novavax—use different technology, with Novavax’s version taking significantly longer to produce. This raises questions about flexibility when outbreaks shift quickly. The FDA once required extra testing for certain age groups, making updates slower, but recent policies suggest a faster track may now be acceptable. Public health advice has also flipped. The CDC stopped recommending vaccines for everyone last year, pushing people to discuss shots with their doctors instead. Now experts must weigh whether updating the vaccine formula will make enough difference to justify the change. Early data shows XFG caused most cases in April, but will that still hold when shots arrive in late 2026? The answer could shape future vaccine campaigns worldwide.